Determination Imatinib Mesylate on Obelisc R Column

HPLC Method for Imatinib mesylate on Obelisc R by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Imatinib mesylate.

Imatinib mesylate is a classified as a signal transduction inhibitor with the chemical formula C29H31N7O. It is an oral targeted therapy medication that is effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. Commercial versions of the drug were a topic of controversy when cancer specialists published a letter condemning the high costs of cancer treatments.

Imatinib mesylate can be retained on an Obelisc R column, which has both positive and negative ion-pairs embedded in the stationary phase, allowing for the fine tuning and separation of a wide range of compounds with different ionic properties. Imatinib mesylate can be determined isocratically using a simple MS-compatible mobile phase of acetonitrile (ACN) and water with Ammonium Formate (AmFm) buffer and detected by UV at 270nm, ELSD, CAD or LC/MS.

Condition
Column Obelisc R, 4.6 x 150 mm, 5 µm, 100 A, dual ended
Mobile Phase MeCN -50%
Buffer Ammonium Formate pH 3.0 – 50 mM
Flow Rate 1.0 ml/min
Detection UV 270nm

 

Description
Class of Compounds
  Drug
Analyzing Compounds Imatinib mesylate

 

Application Column

Obelisc R

Column Diameter: 4.6 mm
Column Length: 150 mm
Particle Size: 5 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Imatinib mesylate
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.